Higher doses of liver drug tested for hepatitis c patients
NCT ID NCT00200343
Summary
This study tested whether higher daily doses of the medication ursodeoxycholic acid (UDCA) were better than a low dose at reducing liver inflammation in people with chronic hepatitis C. Nearly 600 participants in Japan took different doses of the drug for 24 weeks. The main goal was to see which dose most improved key markers of liver health found in blood tests.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Gastroenterology, University of Tokyo
Hongo, Bunkyo-ku, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.